Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Nuclear factor kappa B pathway associated biomarkers in AIDS defining malignancies
Juan-Carlos Ramos; Sang-Hoon Sin; Michelle R. Staudt; Debasmita Roy; Wolfgang Vahrson; Bruce J. Dezube; William Harrington Jr.; Dirk P. Dittmer (Profiled Author: Dirk P Dittmer)
International Journal of Cancer. 2012;130(11):2728-2733.
AbstractThe nuclear factor kappa B (NFκB) pathway is essential for many human cancers. Therapeutics such as bortezomib (Velcade™) that interfere with NFκB signaling are of great clinical interest. NFκB signaling, however, is multifaceted and variable among tissues, developmental and disease entities. Hence, targeted biomarkers of NFκB pathways are of prime importance for clinical research. We developed a novel real-time qPCR-based NFκB array. Only mechanistically validated NFκB targets were included. We then used random-forest classification to define individual genes and gene combinations within the NFκB pathways that define viral lymphoma subclasses as well as Kaposi sarcoma (KS). Few NFκB targets emerged that were universally present in all tumor types tested, underscoring the need for additional tumor-type specific biomarker discovery. (i) We uncovered tissue of origin-specific tumor markers, specifically CD69, CSF-1 and complement factor B (C1QBP) for primary effusion lymphoma (PEL); IL1-beta, cyclinD3 and CD48 for KS. We found that IL12, jun-B, msx-1 and thrombospondin 2 were associated with EBV co-infection in PEL. (ii) We defined the NFκB signature of Epstein-Barr virus (EBV) positive AIDS-associated Burkitt lymphoma (BL). This signature identified CCR5 as the key marker. (iii) This signature differed from EBV negative BL consistent with the idea that EBV not only activates NFκB activity but that this virus also reprograms NFκB signaling toward different targets. Copyright © 2011 UICC.
PMID: 21792887 PMCID: PMC3265660
Scientific Context
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Related Publications
-
1.
2005Motoki Kurokawa; Subrata K. Ghosh; Juan Carlos Ramos; Abdul M. Mian; Ngoc L. Toomey; Lisa Cabral; Denise Whitby; Glen N. Barber; Dirk P. Dittmer; William J. Harrington Jr.
Azidothymidine inhibits NF-κB and induces Epstein-Barr virus gene expression in Burkitt lymphoma
Blood. 2005;106(1):235-240. -
2.
2002J.J. Hille; J. Webster-Cyriaque; J.M. Palefski; N. Raab-Traub
Mechanisms of expression of HHV8, EBV and HPV in selected HIV-associated oral lesions
Oral Diseases. 2002;8(SUPPL. 2):161-168. -
3.
2003Dirk P. Dittmer
Cancer Research. 2003;63(9):2010-2015.
Related Experts
Author of this Document
-
Internal ExpertsPublications
-
162
-
246
-
97
-
117
-
32
-
23
